| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSA |
| Uniprot No | P10619 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-480aa |
| 氨基酸序列 | AP DQDEIQRLPG LAKQPSFRQY SGYLKGSGSK HLHYWFVESQ KDPENSPVVL WLNGGPGCSS LDGLLTEHGP FLVQPDGVTL EYNPYSWNLI ANVLYLESPA GVGFSYSDDK FYATNDTEVA QSNFEALQDF FRLFPEYKNN KLFLTGESYA GIYIPTLAVL VMQDPSMNLQ GLAVGNGLSS YEQNDNSLVY FAYYHGLLGN RLWSSLQTHC CSQNKCNFYD NKDLECVTNL QEVARIVGNS GLNIYNLYAP CAGGVPSHFR YEKDTVVVQD LGNIFTRLPL KRMWHQALLR SGDKVRMDPP CTNTTAASTY LNNPYVRKAL NIPEQLPQWD MCNFLVNLQY RRLYRSMNSQ YLKLLSSQKY QILLYNGDVD MACNFMGDEW FVDSLNQKME VQRRPWLVKY GDSGEQIAGF VKEFSHIAFL TIKGAGHMVP TDKPLAAFTM FSRFLNKQPY |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CTSA(组织蛋白酶A)重组蛋白的参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*"Expression and Characterization of Recombinant Human Cathepsin A in Pichia pastoris"*
**作者**：Zhang Y, Wang L, et al.
**摘要**：该研究利用毕赤酵母表达系统成功表达了重组人CTSA蛋白，并通过亲和层析纯化获得高纯度产物。酶活实验证实重组CTSA具有水解底物的活性，并表现出与天然蛋白相似的pH依赖性，为后续功能研究奠定了基础。
2. **文献名称**：*"Structural and Functional Analysis of Recombinant CTSA in Lysosomal Multienzyme Complex Assembly"*
**作者**：Suzuki K, Yamamoto K.
**摘要**：作者通过哺乳动物细胞表达重组CTSA，发现其作为溶酶体多酶复合体的支架蛋白，对β-半乳糖苷酶和神经氨酸酶的稳定性至关重要。研究揭示了CTSA通过C端结构域介导复合体组装的功能机制。
3. **文献名称**：*"Development of a Therapeutic Recombinant CTSA for GM1 Gangliosidosis"*
**作者**：Reynaud D, et al.
**摘要**：该研究开发了一种重组CTSA替代疗法，用于治疗GM1神经节苷脂贮积症。在小鼠模型中，重组蛋白通过血脑屏障递送，显著减少溶酶体贮积物并改善神经功能，证明了其治疗潜力。
---
**注**：以上文献为示例性质，具体内容需根据实际研究调整。建议通过PubMed或Web of Science以关键词“recombinant cathepsin A”或“CTSA expression”检索最新文献。
**Background of CTSA Recombinant Protein**
Cathepsin A (CTSA), also known as lysosomal carboxypeptidase A or protective protein, is a multifunctional enzyme encoded by the *CTSA* gene. It belongs to the serine carboxypeptidase family and plays a critical role in lysosomal protein degradation, cellular homeostasis, and post-translational modification of bioactive peptides. Structurally, CTSA exists as a homodimer or part of a multi-enzyme complex with β-galactosidase and neuraminidase-1. stabilizing these enzymes and modulating their activity.
CTSA’s enzymatic activity includes carboxypeptidase, deamidase, and esterase functions, impacting processes like peptide hormone inactivation (e.g., substance P) and lipid metabolism. Notably, CTSA deficiency is linked to *galactosialidosis*, a rare lysosomal storage disorder characterized by impaired degradation of glycoproteins, leading to systemic complications such as neurodegeneration, skeletal abnormalities, and organomegaly. Additionally, CTSA interacts with endothelial cells and has been implicated in cardiovascular diseases, including hypertension and heart failure, due to its role in regulating vasoactive peptides.
Recombinant CTSA protein is produced using biotechnological platforms (e.g., mammalian or bacterial expression systems) to study its structure-function relationships, develop enzyme replacement therapies for galactosialidosis, or explore its therapeutic potential in metabolic and cardiovascular disorders. Its recombinant form allows for controlled studies on lysosomal biology, substrate specificity, and inhibitor screening. Advances in protein engineering have also enabled the design of CTSA variants with enhanced stability or modified activity, supporting both basic research and translational applications.
In summary, CTSA recombinant protein serves as a vital tool for understanding lysosomal dysfunction mechanisms and developing targeted treatments for related genetic and acquired diseases.
×
